Microbix Biosystems has introduced the new Omicron variant swab-formatted test control, expanding its portfolio of quality assessment products (QAPs).

The new test control helps to validate the integrity and accuracy of nucleic-acid based tests’ workflows for the SARS-CoV-2 Wuhan strain and Omicron variant.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The company is commercialising its in-vitro diagnostic (IVD) quality controls that can help to improve the workflow accuracy of clinical laboratory PCR tests, which aim to identify and differentiate the Wuhan strain and Omicron variant of SARS-CoV-2.

The Omicron QAP is developed using COPAN FLOQSwabs and is labelled as REDx FLOQ SARS-CoV-2 B.1.1.529 Swab Positive Control.

It offers a comprehensive and cost-effective quality management tool that helps avoid systemic errors made by consumables, technicians or instruments.

Microbix Biosystems CEO and president Cameron Groome said: “For optimal patient care and public health management, clinicians and lab directors need controls that can provide them justifiable confidence in the accuracy and reliability of their testing programmes.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Microbix’s suite of QAPs to support testing for respiratory pathogens is providing that essential support, driven by our ability to quickly respond to the emergence of new viruses or variants with pandemic-generating potential.

“We are pleased to add this Omicron-oriented QAP to maintain our complete coverage of all major Covid variants.”

The company stated that the QAP is currently available to support the quality management systems of clinical laboratories, covering central labs, as well as point-of care workflows in Canada and the US.

Last December, Microbix Biosystems introduced the new Multiplex Respiratory PCR-Test Control, which is branded as REDx FLOQ SARS-CoV-2/Flu A&B/RSV Swab Positive Control.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact